Launch Uptake Analogs
When a new drug comes out, a company wants to know how fast it might be taken up. This lines up similar drugs from the year each one launched and shows what Medicare and Medicaid spent on them, and how many prescriptions they filled, in each year after.
Medicare Part D spending for GLP-1 receptor agonists, year by year from each brand's first year on the market, so their ramps line up.
- Brands lined up: 9, 2 launched before 2012
- Median spending, year 3: $455M
- Fastest to $1B a year: Mounjaro, year 2
- Years covered: 2012–2025
Medicare Part D Spending by Year Since Launch
Year 1 is each brand's first calendar year with Medicare Part D claims, usually a part year. Gross spending before rebates.
The Analogs
Medicare Part D spending by year since launch. Already on the market in 2012, so left out of the curves: Byetta, Victoza.| Part D coverage | |||||||
|---|---|---|---|---|---|---|---|
| TanzeumAlbiglutide | 2014 | $826K | $16.2M | $34.8M | $0 | $0 | — |
| TrulicityDulaglutide | 2014 | $150K | $35.7M | $269M | $1.36B | $4.83B | Plans and tiers |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 2017 | $6.2M | $33.8M | $80.4M | $166M | $275M | Plans and tiers |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 2017 | $2.9M | $26.8M | $56.4M | $75.8M | $61.9M | Plans and tiers |
| OzempicSemaglutide | 2018 | $56.8M | $552M | $1.46B | $4.63B | $16.2B | Plans and tiers |
| RybelsusSemaglutide | 2019 | $367K | $73.4M | $455M | $1.67B | $2.03B | — |
| MounjaroTirzepatide | 2022 | $144M | $2.36B | $6.34B | — | $14.1B | Plans and tiers |
| WegovySemaglutide | 2023 | $200K | $301M | $1.03B | — | $1.03B | Plans and tiers |
| ZepboundTirzepatide | 2024 | $387K | $1.04B | — | — | $1.04B | Plans and tiers |
Part D spending and claims by brand, 2012 to 2025: each year from the newest of CMS's yearly dashboards that covers it, and 2025 from its quarterly file. Gross spending, before manufacturer rebates and discounts. A brand's presentations (pens, syringes, starter packs) are added together. Year 1 is the first year with claims; a brand already paid for in the first year listed counts as launched then only if that year's claims were under 5% of the next year's. Classes group brands whose ingredient shares a mechanism of action or target in ChEMBL (CC BY-SA 3.0); the named classes match ChEMBL's mechanism text. Drugs given in clinics (Part B) are not in these files. Refreshed weekly. CMS, Medicare Part D Spending by Drug